51047-59-7 Usage
General Description
2-Methyl-6-piperazin-1-ylpyrazine is a chemical compound commonly used in the creation of fragrances and flavors. It is a heterocyclic compound that belongs to the class of pyrazines, which are known for their pleasant and characteristic odor. 2-METHYL-6-PIPERAZIN-1-YLPYRAZINE is often used as a flavoring agent in food and beverages due to its strong, earthy, and nutty aroma. Additionally, it is used in the production of perfumes and scented products due to its aromatic properties. 2-Methyl-6-piperazin-1-ylpyrazine is also utilized in the pharmaceutical industry for the synthesis of various pharmaceutical drugs and is considered a valuable building block for organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 51047-59-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,0,4 and 7 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 51047-59:
(7*5)+(6*1)+(5*0)+(4*4)+(3*7)+(2*5)+(1*9)=97
97 % 10 = 7
So 51047-59-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H14N4/c1-8-6-11-7-9(12-8)13-4-2-10-3-5-13/h6-7,10H,2-5H2,1H3
51047-59-7Relevant articles and documents
OGA INHIBITOR COMPOUNDS
-
Page/Page column 61; 63, (2021/06/26)
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
